Clinical Trial Update: Early Clinical Study on the Use of Donor-derived EBV-specific T Cells for the Prevention of EBV Infection After Allogeneic Hematopoietic Stem Cell Transplantation [EARLY_Phase 1]

View source ↗

Summary

An early Phase 1 study assessing donor-derived EBV-specific T cells to prevent Epstein-Barr virus infection after allogeneic hematopoietic stem cell transplanta…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epstein-barr Virus Infection

Drugs mentioned

• Donor-derived EBV-specific T cells (EBV-specific T cells)

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Prevention of EBV Infection After Allogeneic Hematopoietic Stem Cell Transplantation | EARLY_Phase 1 | Status: NOT_YET_RECRUITING